ResponseDX: Colon and ResponseDX: Lung are proprietary PCR-based tests in a panel, which include the analysis of KRAS mutation and serve to help physicians with therapeutic treatment decisions for patients with non-small cell lung cancer and colorectal cancer.
In addition to Response Genetics offering its ResponseDX tests through its own newly formed specialized sales team, and under the terms of the agreement, NeoGenomics will be the exclusive national clinical reference laboratory authorized to offer Response Genetics’s proprietary tests through their own proven national sales force. All tests will be performed through Response Genetics’s Clinical Laboratory Improvement Amendment-certified laboratory.
Robert Gasparini, president and chief scientific officer of NeoGenomics, said: “We could not be more pleased than to have Response Genetics as a partner in this endeavor. We believe this combination of two leaders in molecular diagnostics will allow us to establish new accounts, differentiate our services, and increase our footprint in the expanding field of molecular cancer genetics.”